Heart Failure (HF) is also known as congestive HF. It is also bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right-side HF (when the heart is unable to fill itself with enough blood). Another term for HF is corpulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle. As the heart weakens, certain proteins and substances are released into the blood which leads to a toxic effect on the heart and blood flow which worsens HF. The causes of HF include ischemic heart disease, diabetes, high blood pressure, lifestyle, and other heart conditions or diseases.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/chronic-heart-failure-market
The Chronic Heart Failure Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Chronic Heart Failure market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Chronic Heart Failure treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chronic Heart Failure Market Key Facts
-
The total diagnosed prevalent cases of Heart Failure in 7MM were estimated to be 29,290,834 in 2020. Among 7MM, the US reported the highest number of prevalent cases of with 6,759,034 cases in 2020.
-
It is estimated that the Gender-specific prevalent cases of Heart Failure in France were 1,403,489 in males and 6,753,958 in females in 2020 respectively.
-
As per the DelveInsight analysis, the total prevalent cases of HF in Italy was found to be 11,201,106 cases in 2020.
-
In 2020, the diagnosed prevalent cases in Japan were estimated to be 4,647,989 cases.
-
In 2020, the Heart Failure (HF) related comorbidities in the US had 3,916,953, 4,897,440, 2,991,401, and 4,840,842 cases of Diabetes, Respiratory Disease, Cardiovascular Diseases, and others respectively.
-
As per the study by Ambrosy et al. (2014), HF is a global public health problem affecting an estimated 26 million worldwide. In the US alone, the prevalence is 5.7 million, and there are 670,000 new cases per year. Among the countries represented by the European Society of Cardiology (ESC), there are an additional 15 million patients with HF.
Key Benefits of Chronic Heart Failure Market Report
-
The market report provides an in-depth analysis of Chronic Heart Failure Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
-
The report will help in developing business strategies by understanding the Chronic Heart Failure Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
-
The market report covers the Chronic Heart Failure current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
-
The report provides a detailed assessment of the Chronic Heart Failure market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
Chronic Heart Failure Market
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Chronic Heart Failure market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Chronic Heart Failure market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Request for Sample @ Chronic Heart Failure Therapeutics Market Assessment
Chronic Heart Failure Epidemiology
The epidemiology section covers insights about the historical and current Chronic Heart Failure patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Chronic Heart Failure Epidemiology Segmentation-7MM
-
Prevalent Population of Heart Failure
-
Diagnosed Prevalent Population of Heart Failure
-
Gender-specific diagnosed prevalent cases of Heart Failure
-
Age-specific diagnosed prevalent cases of Heart Failure
-
Type-specific diagnosed prevalence of Heart Failure (Acute and Chronic)
-
NYHA class-specific diagnosed prevalent cases
-
Diagnosed prevalent cases of Heart Failure with Ejection Fraction
-
Diagnosed Prevalent cases of Heart Failure associated with comorbidities
Chronic Heart Failure Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Heart Failure market or expected to get launched in the market during the study period. The analysis covers Chronic Heart Failure market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Chronic Heart Failure Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Table of Content
1. Key Insights
2. Executive Summary
3. Chronic Heart Failure Competitive Intelligence Analysis
4. Chronic Heart Failure Market Overview at a Glance
5. Chronic Heart Failure Disease Background and Overview
6. Chronic Heart Failure Patient Journey
7. Chronic Heart Failure Epidemiology and Patient Population
8. Chronic Heart Failure Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Heart Failure Unmet Needs
10. Key Endpoints of Chronic Heart Failure Treatment
11. Chronic Heart Failure Marketed Products
12. Chronic Heart Failure Emerging Therapies
13. Chronic Heart Failure Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Heart Failure Market Outlook (7 major markets)
16. Chronic Heart Failure Access and Reimbursement Overview
17. KOL Views on the Chronic Heart Failure Market.
18. Chronic Heart Failure Market Drivers
19. Chronic Heart Failure Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/chronic-heart-failure-market
Latest Reports By DelveInsight
Chronic Heart Failure Pipeline Insights
Chronic Heart Failure Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Chronic Heart Failure market.
Corneal Endothelial Dystrophy Market
DelveInsight’s “Corneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Corneal Endothelial Dystrophy market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/